Development of Stability Indicating Densitometric Method for Estimation of Tegoprazan used in the Treatment of Gastroesophageal Reflux Disease

Year 2026, Volume: 30 Issue: 1, 237 - 245, 11.01.2026

Mitalben Parmar , Dimal Shah , Usmangani Chhalotiya

https://doi.org/10.12991/jrespharm.1631220

https://izlik.org/JA62ZN23HM

Abstract

Novel drug Tegoprazan has been introduced for the treatment of gastro-esophageal reflux disease. Accurate and precise thin layer chromatographic method has been developed and validated for estimation of tegoprazan. Silica gel G 60 F254 (20cm×20cm) coated aluminium backed plates were used as stationary phase and mixture of Toluene: Methanol (7.5: 2.5 v/v) was used as mobile phase. The compact band (Rf values 0.53 ± 0.1) was obtained for Tegoprazan. The method was found to be linear in the concentration range of 100 -700 ng/band with a linear regression equation showing linear relationship with R2 =0.9944. The method was validated as per ICH Q2 (R2) guidelines Forced degradation studies were carried out to assess molecule’s intrinsic stability, using acid and base hydrolysis, oxidative stress and photolytic degradation. Forced degradation study revealed that Tegoprazan was highly susceptible to acid hydrolysis. Greenness assessment for develop method was conducted using AGREE and White analytical chemistry. The evaluation confirmed environmentally friendly nature of developed method.

Keywords

Validation , forced degradation study , gastroesophageal reflux disease , High performance thin layer chromatography

References

• [1] Gyawali CP, Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology.2018;154(2):302-318. https://doi.org/10.1053/j.gastro.2017.07.049
• [2] Maradey-Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2014;20:6-16. http://dx.doi.org/10.5056/jnm.2014.20.1.6
• [3] Kim DK, Lee KH, Kim SJ, Kim SJ, Lee SJ, Park CH, Kim BT, Song GS, Moon BS, Ryu SY. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease. J Pharmacol Exp Ther. 2019;369(3):318-327. https://doi.org/10.1124/jpet.118.254904.
• [4] Andersson K, Carlsson E. Potassium -competitive acid blockade: A new therapeutic strategy in acid related diseases. Pharmacol Ther. 2005; 108 (3):294-307. http://dx.doi.org/10.1016/j.pharmthera.2005.05.005
• [5] Kubo K, Kimura N, Kato M. Potassium-competitive acid blocker-associated gastric mucosal lesions. Clin Endosc. 2024;57(4):417-423. https://doi.org/10.5946/ce.2023.279.
• [6] Takahashi N, Take Y. Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility. J Pharmacol Exp Ther.2018;363(2):275-286. https://doi.org/10.1124/jpet.117.244202
• [7] Cho YK, Choi MG, Choi SC, Lee KM, Kim TO, Park SH, Moon JS, Lim YJ, Kang DH, Cheon GJ, Baik GH, Kim KO, Cho KB, Jang JS, Park JJ, Son BK, Jung HK, Kim BW, Kim SK, Lee ST, Cha JM, Kim AR, Kim EJ, Park HW, Song GS. Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment Pharmacol Ther. 2020;52(5):789-797. https://doi.org/10.1111/apt.15865
• [8] Lee KJ, Son BK, Kim GH, Jung HK, Jung HY, Chung IK, Sung IK, Kim JI, Kim JH, Lee JS, Kwon JG, Park JH, Huh KC, Park KS, Park MI, Kim N, Lee OY, Jee SR, Lee SK, Youn SJ, Kim SK, Lee ST, Hong SJ, Choi SC, Kim TN, Youn YH, Park HJ, Kang MJ, Park CH, Kim BT, Youn S, Song GS, Rhee PL. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49(7):864-872. https://doi.org/10.1111/apt.15185
• [9] Yang E, Ji SC, Jang IJ, Lee S. Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole. Clin Pharmacokinet. 2023;62(4):599-608. https://doi.org/10.1007/s40262-023-01228
• [10] Oh M, Lee H, Kim S, Kim B, Song GS, Shin JG, Ghim JL. Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects. Transl Clin Pharmacol. 2023;31(2):114-123. https://doi.org/10.12793/tcp.2023.31.e11
• [11] Zheng H, Yuan S, Liu J. Efficacy and safety of tegoprazan in the treatment of gastroesophageal reflux disease: A protocol for meta-analysis and systematic review. PLoS One. 2024;19(5):e0302450. https://doi.org/10.1371/journal.pone.0302450.
• [12] K-CAB® | Products | RaQualia Pharma Inc, https://www.raqualia.com/en/products/tegoprazan.html. (assessed on 28th January 2025)
• [13] Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based Therapies. Drug Metabolism and Pharmacokinetics. 2005: 20(3): 153-167. https://doi.org/10.2133/dmpk.20.153
• [14] Yang E, Ji SC, Jang IJ, Lee SH. Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole. Clin Pharmacokinet. 2023;62:599–608. https://doi.org/10.1007/s40262-023-01228-4.
• [15] Lee SC, Kim M, Kim D, Kyung E, Eun J, Lee H. Development of a patient ‑ centric formulation of tegoprazan , a novel potassium ‑ competitive acid blocker , using modified ‑ release drug ‑ coated pellets. J Pharm Investig. 2022;52(5):623–638. https://doi.org/10.1007/s40005-022-00582
• [16] Zhang L, Duan S, Xu S, Wang L, Shen Y. Determination of enantiomeric impurity in tegoprazan drug substance by HPLC. SSC Plus.2024; 11(7): e202400125. https://doi.org/10.1002/sscp.202400125
• [17] Kim J, Kim S, Noh HJ, Ryu SY, Kim SJ. Simultaneous quantification of tegoprazan and its major metabolite M1 in dog plasma using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal.2019;171:99–103. https://doi.org/10.1016/j.jpba.2019.03.045.
• [18] Guo K, He X, Zhao H, Ma C. Characterisation of degradation products of tegoprazan by LC-MS and GC-MS. J Pharm Biomed Anal.2023;228(01):115323. https://doi.org/10.1016/j.jpba.2023.115323
• [19] Parys W, Pyka-Pająk A. TLC-Densitometry for Determination of Omeprazole in Simple and Combined Pharmaceutical Preparations. Pharmaceuticals (Basel). 2022 ;15(8):1016. https://doi.org/10.3390/ph15081016
• [20] Pena-Pereira F, Wojnowski W, Tobiszewski M. AGREE - Analytical GREEnness Metric Approach and Software. Anal Chem. 2020;92(14):10076–10082. https://dx.doi.org/10.1021/acs.analchem.0c01887.
• [21] Pena-Pereira F, Tobiszewski M, Wojnowski W, Psillakis E. A Tutorial on AGREEprep an analytical greenness metric for sample preparation. Adv Sample Prep. 2022;3(06):100025. https://doi.org/10.1016/j.sampre.2022.100025
• [22] Płotka-Wasylka J, Wojnowski W. Complementary green analytical procedure index (ComplexGAPI) and software. Green Chem. 2021;23(21):8657–8665. http://xlink.rsc.org/?DOI=d1gc02318g.
• [23] Solanki KH, Solanki DP, Shah DA, Chhalotiya UK, Kachhiya HM, Tandel JN, Parmar MS. HPTLC–densitometric method of analysis for estimation of efonidipine hydrochloride and telmisartan used in treatment of hypertension. J Liq Chromatogr Relat Technol. 2024;47(16-20):368-377. https://doi.org/10.1080/10826076.2024.2397634
• [24] Mansour FR, Omer KM, Płotka-Wasylka J. A total scoring system and software for complex modified GAPI (ComplexMoGAPI) application in the assessment of method greenness. Green Anal Chem. 2024;10:100126. https://doi.org/10.1016/j.greeac.2024.100126.
• [25] ICH. International commission on harmonisation. ICH Q2 (R2) validation of analytical procedures. Eur agency Eval Med Prod. 2023;2(December 2023). https://www.ema.europa.eu/en/ich-q2r2-validation-analytical-procedures-scientific-guideline
• [26] Ahuja Satinder and Dong Michael, Handbook of Pharmaceutical Analysis by HPLC. Noida: Elsevier, a division of Elsevier India Private Limited, Sixth Volume; 2009, p. 337-340
• [27] K-CAB film -coated tablets 50 mg. Accessed on 28th Jan 2025. K-CAB FILM-COATED TABLETS _ myHealthbox.pdf